Literature DB >> 22939241

Therapeutic management of uterine fibroid tumors: updated French guidelines.

Henri Marret1, Xavier Fritel, Lobna Ouldamer, Sofiane Bendifallah, Jean-Luc Brun, Isabelle De Jesus, Jean Derrien, Géraldine Giraudet, Vanessa Kahn, Martin Koskas, Guillaume Legendre, Jean Philippe Lucot, Julien Niro, Pierre Panel, Jean-Pierre Pelage, Hervé Fernandez.   

Abstract

The medical management of symptomatic non-submucosal uterine fibroid tumors (leiomyomas or myomas) is based on the treatment of abnormal uterine bleeding by any of the following: progestogens, a levonorgestrel-releasing intrauterine device, tranexamic acid, nonsteroidal anti-inflammatory drugs, or GnRH analogs. Selective progesterone receptor modulators are currently being evaluated and have recently been approved for fibroid treatment. Neither combined estrogen-progestogen contraception nor hormone treatment of the menopause is contraindicated in women with fibroids. When pregnancy is desired, whether or not infertility is being treated by assisted reproductive technology, hysteroscopic resection in one or two separate procedures of submucosal fibroids less than 4 cm in length is recommended, regardless of whether they are symptomatic. Interstitial, also known as intramural, fibroids have a negative effect on fertility but treating them does not improve fertility. Myomectomy is therefore indicated only for symptomatic fibroids; depending on their size and number, and may be performed by laparoscopy or laparotomy. Physicians must explain to women the potential consequences of myomas and myomectomy on future pregnancy. For perimenopausal women who have been informed of the alternatives and the risks, hysterectomy is the most effective treatment for symptomatic fibroids and is associated with a high rate of patient satisfaction. When possible, the vaginal or laparoscopic routes should be preferred to laparotomy for hysterectomies for fibroids considered typical on imaging. Because uterine artery embolization is an effective treatment with low long-term morbidity, it is an option for symptomatic fibroids in women who do not want to become pregnant, and a validated alternative to myomectomy and hysterectomy that must be offered to patients. Myolysis is under assessment, and research on its use is recommended. Isolated laparoscopic ligation of the uterine arteries is a potential alternative to uterine artery embolization; it also complements myomectomy by reducing intraoperative bleeding. It is possible to use second-generation techniques of endometrial ablation to treat submucosal fibroids in women whose families are complete. Subtotal hysterectomy is a possible alternative to total hysterectomy for fibroid treatment, given that by laparotomy the former has a lower complication rate than the latter, while by laparoscopy, these rates are the same. In each case, the patient is informed about the benefit and risk associated with each therapeutic option.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22939241     DOI: 10.1016/j.ejogrb.2012.07.030

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  23 in total

1.  Moving Toward Individualized Medicine for Uterine Leiomyomas.

Authors:  Shannon K Laughlin-Tommaso; Elizabeth A Stewart
Journal:  Obstet Gynecol       Date:  2018-10       Impact factor: 7.661

2.  Consensus Meetings Regarding Uterine Artery Embolization and Focused Ultrasound in Fibroid Treatment: an Analysis.

Authors:  Thomas Kröncke; Matthias David; Matthias Fritz Matzko
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-06-28       Impact factor: 2.915

Review 3.  Drug delivery for the treatment of endometriosis and uterine fibroids.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

4.  Transarterial embolization of hypervascular tumors using trisacryl gelatin microspheres (Embosphere): a prospective multicenter clinical trial in Japan.

Authors:  Keigo Osuga; Yasuo Nakajima; Miyuki Sone; Yasuaki Arai; Yoshihiro Nambu; Shinichi Hori
Journal:  Jpn J Radiol       Date:  2016-03-10       Impact factor: 2.374

Review 5.  Epigenomic and enhancer dysregulation in uterine leiomyomas.

Authors:  Oliwia W Mlodawska; Priyanka Saini; J Brandon Parker; Jian-Jun Wei; Serdar E Bulun; Melissa A Simon; Debabrata Chakravarti
Journal:  Hum Reprod Update       Date:  2022-06-30       Impact factor: 17.179

6.  A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years.

Authors:  D D Baird; T M Saldana; D L Shore; M C Hill; J M Schectman
Journal:  Hum Reprod       Date:  2015-09-25       Impact factor: 6.918

7.  How to differentiate benign from malignant myometrial tumours using MR imaging.

Authors:  Isabelle Thomassin-Naggara; Sophie Dechoux; Claire Bonneau; Audrey Morel; Roman Rouzier; Marie-France Carette; Emile Daraï; Marc Bazot
Journal:  Eur Radiol       Date:  2013-04-08       Impact factor: 5.315

8.  Quality of ultrasonography reporting and factors associated with selection of imaging modality for uterine fibroids in Canada: results from a prospective cohort registry.

Authors:  Olga Bougie; Mohamed A Bedaiwy; Philippe Laberge; Gerald Lebovic; Nicholas Leyland; Mostafa Atri; Ally Murji
Journal:  CMAJ Open       Date:  2020-08-12

9.  Comparison of Laparoscopic Myomectomy with and without Uterine Artery Occlusion in Treatment of Symptomatic Multiple Myomas.

Authors:  YanZhen Peng; JiuMei Cheng; ChunYi Zang; Xi Chen; JinXue Wang
Journal:  Int J Gen Med       Date:  2021-05-05

10.  Use of Chinese medicine correlates negatively with the consumption of conventional medicine and medical cost in patients with uterine fibroids: a population-based retrospective cohort study in Taiwan.

Authors:  Shan-Yu Su; Chih-Hsin Muo; Donald E Morisky
Journal:  BMC Complement Altern Med       Date:  2015-04-23       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.